Providence

 

Recombinant Activated Factor VII for Acute Intracerebral Hemorrhage

The Authors of this study conclude:

"Treatment with rFVIIa within four hours after the onset of intracerebral hemorrhage limits the growth of the hematoma, reduces mortality, and improves functional outcomes at 90 days, despite a small increase in the frequency of thromboembolic adverse events. "

N Engl J Med 2005;352:777-85. (Link)